# Phase IIb Clinical Study to Assess the Efficacy and Safety of GenSci120 Injection in Patients With Moderately to Severely Active RA Who Have an Inadequate Response to at Least One DMARD

> **NCT07423533** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Changchun GeneScience Pharmaceutical Co., Ltd.** · enrollment: 450 (estimated)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** GenSci120 150 mg
- **DRUG:** GenSci120 600 mg
- **DRUG:** GenSci120 1000 mg
- **DRUG:** adalimumab injection 40 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07423533
- **Lead sponsor:** Changchun GeneScience Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02
- **Primary completion:** 2027-09
- **Final completion:** 2028-12
- **Target enrollment:** 450 (ESTIMATED)
- **Last updated:** 2026-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07423533

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07423533, "Phase IIb Clinical Study to Assess the Efficacy and Safety of GenSci120 Injection in Patients With Moderately to Severely Active RA Who Have an Inadequate Response to at Least One DMARD". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07423533. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*